Alnylam Pharmaceuticals, Inc.

OXLUMO

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Alnylam Pharmaceuticals, Inc.

Oxlumo HCPCS:

J0224

HCPCS Code Descriptor:

Injection, lumasiran, 0.5 mg

Category:

J Code

Oxlumo NDCs:

71336-1002-01

Primary Type:

Genetic Disorder

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Subcutaneous

Oxlumo CPT Codes:

Potential CPT administration codes for Oxlumo can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Oxlumo:

OXLUMO is a Genetic Disorder drug manufactured by Alnylam Pharmaceuticals, Inc. and administered via the Subcutaneous route of administration. The J Code: J0224 is aligned to the drug OXLUMO.

ACCESS PRICING AND MORE BY REGISTERING

J0224 Added Date:

July 1, 2021

J0224 Effective Date:

July 1, 2021

J0224 Termination Date:

HCPCS Active

Oxlumo billing and coding information can be found through Alnylam Pharmaceuticals, Inc. at the link below:
Oxlumo patient assistance information can be found through Alnylam Assist at the URL: https://www.alnylamassist.com/
OXLUMO prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for OXLUMO. Please check back in a few weeks.